share_log

Credit Suisse Maintains Underperform on Clover Health Investments, Lowers Price Target to $1.25

Credit Suisse Maintains Underperform on Clover Health Investments, Lowers Price Target to $1.25

瑞信在三葉草健康投資方面保持表現不足,將目標價格降至 1.25 美元
Benzinga ·  2023/03/06 07:31

Credit Suisse analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Underperform and lowers the price target from $2.5 to $1.25.

瑞信分析師喬納森·永保持三葉草健康投資 (NASDAQ: CLOV) 與表現不佳和降低價格目標從 $2.5 至 $1.25.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論